Minocycline for Bipolar Depression
Information source: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bipolar Depression
Intervention: Minocycline (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Icahn School of Medicine at Mount Sinai Official(s) and/or principal investigator(s): Dan V Iosifescu, MD, MSc, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai
Summary
The purpose of this study is to evaluate minocycline as a potential treatment for bipolar
depression when added to a mood-stabilizing medication. Minocycline is an antibiotic that is
approved for the treatment of infections and acne. Participation in this research study is
expected to last 8 weeks, and includes five outpatient visits.
Clinical Details
Official title: Minocycline for Bipolar Disorder
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change in scores on the Montgomery-Asberg Depression Rating Scale (MADRS)
Secondary outcome: Change in N-acetylaspartate (NAA), as measured by 1H-MRS scanChanges in Young Mania Rating Scale (YMRS)
Detailed description:
Bipolar depression remains the great unmet need in the treatment of bipolar disorder. Only
two treatments have been FDA-approved for the management of acute bipolar depression (the
combination of olanzapine and fluoxetine and quetiapine). Early pilot data suggests the drug
minocycline has potent antidepressant effects. Minocycline is approved by the Food and Drug
Administration (FDA) (for acne and bacterial infections), is inexpensive and readily
available in generic formulation, and is generally well-tolerated. This study will examine
whether administering the drug minocycline to individuals with bipolar depression over 8
weeks will improve their depressive symptoms. This study will also offer an option to
participate in proton magnetic resonance spectroscopy (1H-MRS) to measure N-Acetylaspartate
(NAA) levels in the brain, which are thought to be decreased in bipolar disorder.
Eligibility
Minimum age: 18 Years.
Maximum age: 68 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets DSM-IV criteria for Bipolar I Disorder or Bipolar II disorder, depressed phase
- A baseline score of at least 18 on the Montgomery-Asberg Depression Rating Scale
(MADRS)
- Participants on mood stabilizer medication for at least two weeks prior to starting
the study, and must remain on the treatment during the study
- Able to understand English
Exclusion Criteria:
- DSM-IV diagnosis of Bipolar NOS, Cyclothymia, or Schizoaffective Bipolar type
- Pregnant women or women of child bearing potential who are not using a medically
accepted means of contraception (defined as oral contraceptive pill or implant,
condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)
- Serious suicide or homicide risk
- Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
endocrine, neurological, or hematological disease
- Clinical or laboratory evidence of hypothyroidism; if maintained on thyroid
medication must be euthyroid for at least 1 month before visit 1
- Drug/alcohol dependence within past 30 days, or current substance use disorder that
requires detoxification
- Current use of minocycline or history of anaphylactic reaction or intolerance to
minocycline
- Primary clinical diagnosis of antisocial or borderline personality disorder
- Patients with metallic foreign bodies or claustrophobia will be excluded from the MRS
component
Locations and Contacts
Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
Additional Information
Starting date: May 2011
Last updated: August 4, 2015
|